Business Context and Reporting Period
Company: Sanofi-Synthelabo
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Half (H1) and Second Quarter (Q2) of 2002
Date of Filing: July 24, 2002
Accounting Basis: French GAAP (with U.S. GAAP reconciliation provided annually)
Key Financial Metrics
Sales Performance
- H1 2002 Consolidated Sales: 3,680 million euros (up 14.8% on a comparable basis; 16.5% reported).
- Q2 2002 Consolidated Sales: 1,825 million euros (up 14.2% on a comparable basis; 13.6% reported).
- Developed Sales (H1 2002): 4,726 million euros (up 17.7% comparable; 15.2% reported).
Geographical Breakdown (H1 2002 Consolidated Sales)
| Region | H1 2002 (€M) | H1 2001 (€M) | Change (Comparable) | Change (Reported) |
|---|---|---|---|---|
| Europe | 2,173 | 1,926 | +12.8% | +11.2% |
| United States | 756 | 617 | +22.5% | +56.5% |
| Rest of World | 752 | 663 | +13.4% | +4.1% |
| Total | 3,680 | 3,205 | +14.8% | +16.5% |
Product Performance (Developed Sales H1 2002)
- Plavix/Iscover: 1,245 million euros (+35.2% comparable).
- Stilnox/Ambien/Myslee: 634 million euros (+37.0% comparable).
- Aprovel/Avapro/Karvea: 553 million euros (+37.3% comparable).
- Top 15 Products: 2,450 million euros, representing 67% of Group sales.
Profitability, Cash Flow, and Debt
The filing text does not provide specific values for net profit, operating margins, cash flow, debt levels, or liquidity ratios for the period. It only references an outlook for net profit growth.
Material Changes vs. Prior Period
- Structural Changes: The difference between comparable and reported sales growth is primarily due to consolidation changes:
- Full consolidation (100%) of Lorex Pharmaceuticals in the U.S. (previously 49%).
- Change to proportionate consolidation (51%) of the Fujisawa-Sanofi-Synthelabo joint venture in Japan (previously 100%).
- Deconsolidation of Ela Medical (effective May 1, 2001).
- Currency Impact: Net neutral impact on sales growth; positive effects from the U.S. dollar and European currencies were offset by negative effects from the Japanese yen and South American currencies.
- Regional Headwinds: Q2 growth was slightly eased by measures taken by Italian authorities affecting local sales and the economic crisis in Latin America.
Guidance, Outlook, and Risks
Outlook
Management expects net profit attributable to the Group to exceed 25% growth for the full year 2002, before exceptional items and goodwill amortization, barring major adverse events.
Key Events and Contingencies
- Acquisition: Acquired the remaining 51% interest in Lorex Pharmaceuticals from Pharmacia for 761 million euros (April 16, 2002), enabling full consolidation of Ambien profits in the U.S.
- Legal Action: Launched proceedings against Dr. Reddy Laboratories (May 14, 2002) alleging infringement of Plavix patents to defend intellectual property.
- Product Launches & Approvals:
- Arixtra: Launched in several European countries; H1 sales totaled 3.5 million euros.
- Eluxatine: Granted fast-track review by U.S. authorities for metastatic colorectal cancer.
- Plavix: CPMP recommended approval for unstable angina and non Q-wave myocardial infarction.
- Aprovel: European Commission approved for treatment of diabetic renal disease.
Risks
Forward-looking statements are subject to uncertainties including: ability to expand profitably in the U.S., success of R&D programs, protection of intellectual property rights, and risks associated with healthcare reimbursement and pricing reforms (particularly in the U.S. and France).
Investor Verification Checklist
- Verify the impact of the Lorex Pharmaceuticals acquisition on future U.S. sales consolidation.
- Monitor the outcome of the patent infringement lawsuit against Dr. Reddy Laboratories regarding Plavix.
- Assess the commercial uptake of newly launched Arixtra and approved indications for Plavix and Aprovel.
- Review the full-year 2002 results (scheduled for September 2, 2002) to confirm the >25% net profit growth guidance.
- Check for updates on the inventory reduction programs for Plavix and Avapro in the U.S. market.